Form 8-K - Current report:
SEC Accession No. 0001213900-24-099094
Filing Date
2024-11-15
Accepted
2024-11-15 16:05:13
Documents
14
Period of Report
2024-11-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0221417-8k_osthera.htm   iXBRL 8-K 27605
2 PRESS RELEASE ISSUED BY OS THERAPIES INCORPORATED ON NOVEMBER 15, 2024 ea022141701ex99-1_osthera.htm EX-99.1 14496
  Complete submission text file 0001213900-24-099094.txt   222552

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE ostx-20241115.xsd EX-101.SCH 3024
4 XBRL LABEL FILE ostx-20241115_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE ostx-20241115_pre.xml EX-101.PRE 22365
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0221417-8k_osthera_htm.xml XML 3811
Mailing Address 15825 SHADY GROVE ROAD SUITE 135 ROCKVILLE MD 20850
Business Address 15825 SHADY GROVE ROAD SUITE 135 ROCKVILLE MD 20850 410-297-7793
OS Therapies Inc (Filer) CIK: 0001795091 (see all company filings)

EIN.: 825118368 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42195 | Film No.: 241467798
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)